Pharmacy giant CVS has found itself in the crosshairs of another lawsuit accusing it of inflating the prices of generic drugs. The suit, filed in federal court in San Francisco, says the company pulled off a "massive fraud" through a discount program for patients paying cash for prescriptions, Bloomberg reports.
Romanian authorities are investigating 11 drug companies for suspected bribery in the country, echoing an investigation launched in China two years ago that targeted drugmakers such as GlaxoSmithKline for alleged wrongdoing.
The Centers for Medicare & Medicaid Services announced that it is expanding Medicare coverage of speech-generating devices to include devices that generate written messages over email and text. Devices that enable Medicare recipients to electronically interface with a telephone to deliver speech via phone messages are also covered.
One of a handful of obesity devices aiming for the U.S. market has been sidelined. Australian company GI Dynamics has opted, after discussions with the FDA, to terminate its pivotal trial for its EndoBarrier due to safety concerns. The trial had already been placed on hold by the agency in March due to the incidence of hepatic abscess.
India's Biocon easily reached the top end of its offer range for an initial public offering of shares in CRO Syngene, a source said, adding that recent reports of troubles at other Indian companies in the sector had no impact on demand.
The Drugs Controller General of India has moved to create a subcommittee to study the feasibility of online drug sales even in the face of strong opposition from brick-and-mortar pharmacies and as restrictions on such sales are routinely flouted, DNA India newspaper reports.
Selling the Trans-Pacific Partnership to a dozen nations after the details are out may prove something of a challenge, as an article in the Japan Times shows.
According to reports posted on the EudraGMDP site, regulators from Italy recommended bans on specific products made by Jinan Jinda Pharmaceutical in Shandong Province in China and Wuxi Jida Pharmaceutical in Jiangsu City, China, as well as Parabolic Drugs in Haryana, India.
Edwards Lifesciences bumped up its transcatheter heart valve sales estimate for 2015 due to what it anticipates will be a strong U.S. launch for its third-generation TAVR device, Sapien 3. It was approved in June within a day of an FDA approval for a similar device from Medtronic, so the next quarter's earnings will start to tell the tale on how that U.S. next-gen TAVR competition will play out.
FDA investigators found a record-keeping mess at an Indian drug manufacturer that they say raises concerns about the quality of the active pharmaceutical ingredients that it shipped for use in U.S. drugs.